(Q38120494)

English

Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years

scientific article published on July 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

1 reference

based on heuristic

inferred from title

Gillian M Keating

1

object named as

Gillian M Keating

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

publication date

1 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

73

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

1227-1244

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Vaccination against herpes zoster in developed countries: state of the evidence

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Similar herpes zoster incidence across Europe: results from a systematic literature review

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Safety and tolerability of zoster vaccine in adults ≥60 years old.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Safety of Zostavax™--a cohort study in a managed care organization

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Immune senescence and vaccines to prevent herpes zoster in older persons

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Zoster vaccine recommendations: the importance of using a clinically valid correlate of protection

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

The impact of herpes zoster and post-herpetic neuralgia on quality-of-life

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Herpes zoster in Germany: quantifying the burden of disease

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice?

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Discussing the zoster vaccine: an interview with Julie Gerberding, president of Merck Vaccines

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Recommended adult immunization schedule: United States, 2013*.

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom

1 reference

https://api.crossref.org/works/10.1007%2FS40265-013-0088-1

21 January 2018

Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Herpes zoster vaccine awareness among people ≥ 50 years of age and its implications on immunization.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Prospective Study of the Herpes Zoster Severity of Illness

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Roundtable on postherpetic neuralgia--what, why, how long, and what's next?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of zoster vaccine in elderly adults following documented herpes zoster

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studying Physician Knowledge, Attitudes, and Practices Regarding the Herpes Zoster Vaccine to Address Perceived Barriers to Vaccination

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Herpes zoster vaccination in people aged 50-59 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Barriers to the use of herpes zoster vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Herpes zoster and postherpetic neuralgia: prevention and management

1 reference

https://pubmed.ncbi.nlm.nih.gov/23839657

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40265-013-0088-1

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38120494&oldid=2201297307"